$4.01
9.80% day before yesterday
Nasdaq, Sep 06, 10:15 pm CET
ISIN
US05280R1005
Symbol
AUTL
Sector
Industry

Autolus Therapeutics plc Stock price

$4.01
+0.11 2.69% 1M
-1.66 29.24% 6M
-2.44 37.81% YTD
+0.96 31.31% 1Y
-3.27 44.91% 3Y
-10.09 71.58% 5Y
-21.00 83.98% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.44 9.80%
ISIN
US05280R1005
Symbol
AUTL
Sector
Industry

Key metrics

Market capitalization $1.07b
Enterprise Value $647.23m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 61.64
P/S ratio (TTM) P/S ratio 101.48
P/B ratio (TTM) P/B ratio 2.02
Revenue growth (TTM) Revenue growth 40.22%
Revenue (TTM) Revenue $10.50m
EBIT (operating result TTM) EBIT $-185.60m
Free Cash Flow (TTM) Free Cash Flow $-160.97m
Cash position $706.96m
EPS (TTM) EPS $-1.16
P/E forward negative
P/S forward 75.97
EV/Sales forward 46.15
Short interest 6.30%
Show more

Is Autolus Therapeutics plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Autolus Therapeutics plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Autolus Therapeutics plc forecast:

8x Buy
80%
2x Hold
20%

Analyst Opinions

10 Analysts have issued a Autolus Therapeutics plc forecast:

Buy
80%
Hold
20%

Financial data from Autolus Therapeutics plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
11 11
40% 40%
100%
- Direct Costs 6.86 6.86
-
65%
3.64 3.64
-
35%
- Selling and Administrative Expenses 53 53
137% 137%
502%
- Research and Development Expense 130 130
6% 6%
1,235%
-179 -179
12% 12%
-1,702%
- Depreciation and Amortization 6.86 6.86
1% 1%
65%
EBIT (Operating Income) EBIT -186 -186
11% 11%
-1,768%
Net Profit -234 -234
51% 51%
-2,228%

In millions USD.

Don't miss a Thing! We will send you all news about Autolus Therapeutics plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Autolus Therapeutics plc Stock News

Positive
Seeking Alpha
one day ago
Autolus Therapeutics plc has a PDUFA date upcoming for its cell therapy obe-cel, indicated for B-ALL. The FDA will decide whether to approve the drug for commercial use. There is already a cell therapy approved in this indication, as well as Amgen's blincyto, but obe-cel's safety and efficacy profile appears strong. Autolus has taken its time gathering the data required to push for approval, bu...
Neutral
Seeking Alpha
29 days ago
Autolus Therapeutics plc (NASDAQ:AUTL ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Olivia Manser – Director-Investor Relations Christian Itin – Chief Executive Officer Rob Dolski – Chief Financial Officer Conference Call Participants Gil Blum – Needham & Company Asthika Goonewardene – Truist Kelly Shi – Jefferies James Shin – Deutsche Bank Matthew Phipps – W...
Neutral
GlobeNewsWire
about one month ago
LONDON, July 26, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its second quarter 2024 financial results and operational highlights before open of US markets on Thursday, August 8, 2024. Management will host a conference call and webcast at ...
More Autolus Therapeutics plc News

Company Profile

Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Christian Itin
Employees 463
Founded 2014
Website www.autolus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today